戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ing nature's own anti-inflammatory molecule, lipoxin.
2 uired for synthesis of the anti-inflammatory lipoxins.
3 g eicosanoid substrates to anti-inflammatory lipoxins.
4 rocessing, was attenuated in the presence of lipoxins.
5  in severe asthma include underproduction of lipoxins.
6 valuating the therapeutic potential of using lipoxins.
7 s are classified as aspirin-triggered 15-epi-lipoxins.
8 pacity for antiinflammatory and proresolving lipoxins.
9 ive lipid mediators such as leukotrienes and lipoxins.
10 nals provided by a class of molecules called lipoxins.
11 ors blocked LTC4 and increased resolvins and lipoxins.
12 vel possibility for treating KS and PEL with lipoxins.
13 the production of resolvins, protectins, and lipoxins.
14 resolving mediators, including resolvins and lipoxins.
15  5-LOX into epimeric lipoxins, termed 15-epi-lipoxins (15-epi-lipoxin A4 [e-LXA4]).
16      In addition, we compared the effects of lipoxin A(4) (100 nM) with vehicle on basal and LPS-stim
17 10(5) cells; P < .01), whereas SPM including lipoxin A(4) (977 +/- 173 vs 675 +/- 167 pg/2.5 x 10(5)
18                            Aspirin-triggered lipoxin A(4) (ATL, 15-epi-LXA(4)) and leukotriene D(4) (
19      In this study, we report that synthetic lipoxin A(4) (LXA(4)) and 15-epi-LXA(4) (i.e., 15(R)-LXA
20                                              Lipoxin A(4) (LXA(4)) and aspirin-triggered 15-epi-LXA(4
21                                              Lipoxin A(4) (LXA(4)) and docosahexaenoic acid-derived n
22         Here, we investigated the actions of lipoxin A(4) (LXA(4)) and its leukocyte receptor in pulm
23 dins E(2) (PGE(2)), F(2alpha) (PGF(2alpha)), lipoxin A(4) (LXA(4)) and its receptor FPR2/ALX were ana
24 X-2)-derived prostaglandin E(2) (PGE(2)) and lipoxin A(4) (LXA(4)) as pivotal mediators in vivo for r
25                                              Lipoxin A(4) (LXA(4)) can also interact with ALX/FPR2 re
26 ects of PRP on monocyte cytokine release and lipoxin A(4) (LXA(4)) generation.
27                                              Lipoxin A(4) (LXA(4)) is a structurally and functionally
28  the effect of pro-inflammatory mediators on lipoxin A(4) (LXA(4)) production and FPR2/ALX expression
29 a synthetic nonpsychoactive cannabinoid, and lipoxin A(4) (LXA(4)), an eicosanoid formed from sequent
30             The anti-inflammatory eicosanoid lipoxin A(4) (LXA(4)), aspirin-triggered 15-epi-LXA(4),
31                    By inducing production of lipoxin A(4) (LXA(4)), which blocks PGE(2) biosynthesis,
32 s 15-lipoxygenase (15-LOX) and receptors for lipoxin A(4) (LXA(4)), which have been implicated in an
33                                              Lipoxin A(4) also reduced the elastase release from homo
34                  Moreover, aspirin-triggered lipoxin A(4) analog evoked release of the antiphlogistic
35                      Also, aspirin-triggered lipoxin A(4) analog markedly inhibited proinflammatory c
36               For example, aspirin-triggered lipoxin A(4) analog reduced Psi(max), resolvin E1 decrea
37          Administration of aspirin-triggered lipoxin A(4) analog, resolvin E1, or 10,17S-docosatriene
38 ontaining aspirin-triggered resolvin D1 or a lipoxin A(4) analog.
39 rate for the first time a potential role for lipoxin A(4) and its receptor in the resolution of the i
40 ds natural and synthetic peptides as well as lipoxin A(4) and mediates important biological functions
41                  We measured serum levels of lipoxin A(4) and myometrial protein release using ELISA,
42                                We found that lipoxin A(4) and resolvin D1, in solution or incorporate
43 he lipid derivatives resolving D1 and D2 and lipoxin A(4) attenuated HLMC histamine release in a dose
44                                 In addition, lipoxin A(4) displayed a CB(1) receptor-dependent protec
45 emaining; synthesis of the anti-inflammatory lipoxin A(4) from arachidonic acid is also detected.
46 d on ultrastructural analysis, IL-8 release, lipoxin A(4) generation, mucin production, and lipoxygen
47 n wild-type mice but both aspirin and 15-epi-lipoxin A(4) had markedly reduced effects on leukocyte-e
48                                    Levels of lipoxin A(4) in nonpregnant women were 0.48 +/- 0.04 nM,
49 ere we show that the anti-inflammatory lipid lipoxin A(4) is an endogenous allosteric enhancer of the
50  the effects of 15-epi-16-(p-fluoro)-phenoxy-lipoxin A(4) methyl ester, an aspirin-triggered lipoxin
51 at are both generated in vivo and act at the lipoxin A(4) receptor (ALXR/FPRL1) to halt PMN diapedesi
52                             In addition, the Lipoxin A(4) receptor (FPR2/ALX) was used as marker for
53                           We report that the lipoxin A(4) receptor is expressed on spinal astrocytes
54 ceptors for RvD1 gave two candidates--ALX, a lipoxin A(4) receptor, and GPR32, an orphan--that were c
55                 15-lipoxygenase (15-LOX) and lipoxin A(4) receptors (ALX) constitute a LXA(4) circuit
56 nistrations of a synthetic aspirin-triggered lipoxin A(4) signal mimetic, ATLa, to probe dynamics of
57                                              Lipoxin A(4) significantly reduced LPS-induced but not b
58 ased more IL-8, and produced lower levels of lipoxin A(4) than that from patients with mild asthma.
59             Mean +/- SE circulating level of lipoxin A(4) was 5.89 +/- 0.63 nM at 24-wk gestation, wi
60                                              Lipoxin A(4) was detected in brain tissues, did not comp
61                           Aspirin and 15-epi-lipoxin A(4) were shown to inhibit leukocyte trafficking
62 by the proresolving lipoxygenase metabolite, lipoxin A(4), a potent stop signal.
63 of this study was to investigate the role of lipoxin A(4), an anti-inflammatory and proresolution mod
64 ivo and in vitro and that spinal delivery of lipoxin A(4), as well as stable analogues, attenuates in
65 oresolution mediators annexin A1 (AnxA1) and lipoxin A(4), as well as the activating and proinflammat
66 l biosynthesis of lipid mediators, including lipoxin A(4), resolvin D1, and protectin D1.
67 nclude the chemotactic peptide fMet-Leu-Phe, lipoxin A(4), serum amyloid A and beta-amyloid peptides.
68 hat aspirin triggers the synthesis of 15-epi-lipoxin A(4), which increases NO synthesis through eNOS
69 oxin A(4) methyl ester, an aspirin-triggered lipoxin A(4)-stable analog (ATLa), on the protein phosph
70 e ability to trigger the synthesis of 15-epi-lipoxin A(4).
71  the aspirin-triggered lipid mediator 15-epi-lipoxin A(4).
72              miR-181b overexpression blunted lipoxin A4 (0.1-10 nm)- and resolvin D1 (0.01-10 nm)-sti
73      The proresolving lipid mediator, 15-epi lipoxin A4 (15-epi LXA4), plays a critical role in limit
74 ure coinciding with reduced levels of 15-epi-Lipoxin A4 (15-epi LXA4).
75  peptide (AnxA1Ac2-26) and aspirin-triggered lipoxin A4 (15-epi-lipoxin A4), on the cerebral microcir
76                                       15-Epi-lipoxin A4 (15-epi-LXA4) blocked agonist-initiated assoc
77 ival crevicular fluid (GCF) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LT
78 AWFIENEEQEYVQTVK), 2.5 mug/kg] and 15-epimer-lipoxin A4 (15-epi-LXA4; FPR2/ALX specific, 12.5 and 100
79                     Aspirin-triggered 15-epi-lipoxin A4 (ATL) is an endogenous lipid mediator that mi
80                                  We measured lipoxin A4 (LXA4) and leukotriene B4 (LTB4) levels in EB
81 d levels of the proresolving lipid mediators lipoxin A4 (LXA4) and, in the presence of aspirin, 15-ep
82                                        Here, lipoxin A4 (LXA4) attenuated TGF-beta1-induced expressio
83                    We previously showed that lipoxin A4 (LXA4) controls migration of dendritic cells
84  Also, levels of prostaglandin D2 (PGD2) and lipoxin A4 (LXA4) in patients with T1R were significantl
85                                              Lipoxin A4 (LXA4) is a potent endogenous lipoxygenase-de
86                                              Lipoxin A4 (LXA4) is an anti-inflammatory lipid, importa
87                                              Lipoxin A4 (LXA4) is an endogenous lipid mediator with p
88                                              Lipoxin A4 (LXA4) signaling blocks asthmatic responses i
89          Here we investigated the ability of lipoxin A4 (LXA4) stable analogs to regulate airway resp
90 endogenous agonists for Fpr2/3 revealed that lipoxin A4 (LXA4) was generated by platelet/neutrophil a
91                               High levels of lipoxin A4 (LXA4) were detected in sera from infected WT
92 riphosphate when concentrations of 1-1600 nM lipoxin A4 (LXA4) were tested as ligands.
93 y-old mice were treated with NPD1, PEDF+DHA, lipoxin A4 (LXA4), 12- or 15-hydroxyeicosatetraenoic aci
94       In this study, we investigated whether lipoxin A4 (LXA4), a specialized, proresolution lipid me
95                                              Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived ei
96            Pro-resolution mediators, such as lipoxin A4 (LXA4), are produced during inflammation retu
97 cosanoids, such as leukotriene B4 (LTB4) and lipoxin A4 (LXA4), may play a key role during obesity.
98 could favor the biosynthesis of proresolving lipoxin A4 (LXA4).
99 nflammatory and proresolving lipid mediator, lipoxin A4 (LXA4).
100 fects of a specialized proresolving mediator lipoxin A4 (LXA4).
101 miting cell for generating anti-inflammatory lipoxin A4 (LXA4).
102                                     However, lipoxin A4 (LXA4, 0.02-2 microM, a lipid mediator with h
103 ric lipoxins, termed 15-epi-lipoxins (15-epi-lipoxin A4 [e-LXA4]).
104                  Moreover, aspirin-triggered lipoxin A4 activation of neutrophil Fpr2/3 regulated neu
105 alog of ATL, 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4 analog (ATLa), inhibits neutrophil recruitmen
106  of two ALX agonists (W peptide and a stable lipoxin A4 analog) exerted cardioprotection in wild-type
107 as rescued by RvE1, PD1 or aspirin-triggered lipoxin A4 analogue.
108 We have also explored other lipid mediators [lipoxin A4 and 15(S)- and 12(S)-hydroxyeicosatetraenoic
109 tor), conveys the proresolving properties of lipoxin A4 and annexin A1 (AnxA1) and the proinflammator
110 allosteric effects of the endogenous ligands lipoxin A4 and pregnenolone at CB1Rs.
111 receptor 2 (ALX/FPR2) by the lipid mediators lipoxin A4 and resolvin D1 (RvD1) promotes resolution of
112                                              Lipoxin A4 augments host defense in sepsis and reduces P
113 ower levels of LTB4 and increased amounts of lipoxin A4 compared with nontransgenic littermates.
114                          In contrast, 15-epi-lipoxin A4 did not significantly improve the severity of
115                         Pregnenolone but not lipoxin A4 displaced [(3)H]SR141716A, but there was no f
116 lates the secretion of the anti-inflammatory lipoxin A4 in host cells and the viral factors involved
117 reatment, aspirin triggers detectable 15-epi-lipoxin A4 in lung tissue, but not in plasma.
118               In activated whole blood, mean lipoxin A4 levels were decreased in severe compared with
119               We also examined the effect of lipoxin A4 on PP5 activation by IL-2 plus IL-4.
120 n (ATL; 15-epi-lipoxin A4), and blocking the lipoxin A4 receptor (ALX) with a peptide antagonist (Boc
121 e with myeloid-selective expression of human lipoxin A4 receptor (hALX) was prepared and used to eval
122 he AnxA1 receptor (formyl peptide receptor 2/Lipoxin A4 receptor [FPR2/ALX]; IC50 approximately 4 nM)
123 fMLF-R and 89% sequence identity with murine lipoxin A4 receptor cDNA.
124           Furthermore, we tested whether the lipoxin A4 receptor formyl-peptide receptor 2/3 (Fpr2/3;
125                                          The lipoxin A4 receptor FPR2/ALX plays an important part in
126                                         Fpr2/lipoxin A4 receptor is a therapeutic target for initiati
127                                Blocking Fpr2/lipoxin A4 receptor with the antagonist Boc2 reversed th
128 receptor 2/3 (Fpr2/3; ortholog to human FPR2/lipoxin A4 receptor) evoked neuroprotective functions af
129 receptor type 2 (FPR2), also called ALX (the lipoxin A4 receptor), conveys the proresolving propertie
130 rs, including integrins, FPR-like receptor-1/lipoxin A4 receptor, and the epidermal growth factor rec
131       Regulatory mechanisms of ALX/FPR2, the lipoxin A4 receptor, expression have considerable releva
132 vating its receptor formyl peptide receptor2/lipoxin A4 receptor, suppresses cytosolic calcium and de
133 he mRNA for FPR and the structurally related lipoxin A4 receptor, termed ALX; thus, comparable equimo
134 ed microRNA-mediated regulation of ALX/FPR2 (lipoxin A4 receptor/formyl peptide receptor 2) expressio
135                          The presence of the lipoxin A4 receptor/formyl peptidyl receptor (ALX/FPR) i
136 inhibition, pretreatment of eosinophils with lipoxin A4 restored GCR phosphorylation and the proaptop
137 treatment with an ALX/FPRL-1 agonist, 15-epi-lipoxin A4 reversed the enhanced sensitivity of AnxA1 (-
138 factor contributing to the downregulation of lipoxin A4 secretion in host cells.
139 suboptimal doses (10 ng/mouse) of the ligand lipoxin A4 stable analog compared with <10% reduction of
140 enzyme 15-lipoxygenase, which is involved in lipoxin A4 synthesis.
141               The counterregulatory mediator lipoxin A4 was detectable in low picogram amounts, using
142                  Basal circulating levels of lipoxin A4 were also decreased in severe relative to mod
143  and 15(S)-hydroxyeicosatetraenoic acid, and lipoxin A4 were found under these conditions.
144 so called ALX because it is the receptor for lipoxin A4) sustains a variety of biological responses r
145 levels of ASA-triggered lipoxin (ATL; 15-epi-lipoxin A4), and blocking the lipoxin A4 receptor (ALX)
146 using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via t
147 26) and aspirin-triggered lipoxin A4 (15-epi-lipoxin A4), on the cerebral microcirculation after isch
148 3)--ortholog to human FPR2/ALX (receptor for lipoxin A4)--exerted regulatory and organ-protective fun
149 g cytokine IL-6, which was opposed by 15-epi-lipoxin A4, a counter-regulatory mediator, and ALX/FPR2
150 d mediator that mimics the actions of native lipoxin A4, a putative "stop signal" involved in regulat
151 RM) containing a novel lipoxin analog (benzo-lipoxin A4, bLXA4) to promote regeneration of hard and s
152 r 15-deoxy-Delta(12,14)-prostaglandin-J2 and lipoxin A4, both of which are potent inflammation-resolv
153 eased endogenous levels of aspirin-triggered lipoxin A4, effects again mediated by Fpr2/3.
154 acetyl salicylic acid, acting through 15-epi-lipoxin A4, have been shown to be anti-inflammatory in h
155 ) levels of 15-epi-lipoxin A4 (15-epi-LXA4), lipoxin A4, leukotriene B4 (LTB4), prostaglandin E2 (PGE
156 y 'proresolution' lipid mediators, including lipoxin A4, resolvin E1 and protectin D1.
157                                              Lipoxin A4, which binds to FPRL1/LXA4R specifically, dec
158  and V) that mediates the release of PAF and lipoxin A4, which, in turn, are responsible for the subs
159  and 3) revealed that PP5 is a target of the lipoxin A4-induced pathway countering cytokine-induced r
160 d to aspirin-triggered lipoxin (ATL), 15-epi-lipoxin A4.
161  to mediate the anti-inflammatory effects of lipoxin A4.
162  arachidonic acid to lipoxins, predominantly Lipoxin A4.
163 ocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both arachidonic acid products
164 one (PIO) increase the myocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both
165 s were harvested and analyzed for myocardial lipoxin-A4 and 15-epi-LXA4 levels and for COX-2 and 5-li
166 n resulted in a small increase in myocardial lipoxin-A4 levels, which was not statistically significa
167                             In vitro, 15-epi-lipoxin-A4 reduced the proliferation of LAM patient-deri
168                                       15-epi-lipoxin-A4 was identified in exhaled breath condensate f
169 rf-2), cyclooxygenase 2 (COX-2) products, or lipoxin action.
170                            Here we show that lipoxins activate two receptors in DCs, AhR and LXAR, an
171 esolving medicines (NPRM) containing a novel lipoxin analog (benzo-lipoxin A4, bLXA4) to promote rege
172 umerous reports of the beneficial effects of lipoxin analog administration in animal models of inflam
173 hat administration of a metabolically stable lipoxin analog in a mouse model of the chronic airway in
174 de novo KSHV-infected endothelial cells with lipoxin and epilipoxin creates an anti-inflammatory envi
175 gate whether exhaled breath condensate (EBC) lipoxin and leukotriene measurements can noninvasively c
176          Moreover, our findings suggest that lipoxin and related pathways offer novel multi-pronged t
177 Importantly, receptors for aspirin-triggered lipoxin and resolvin E1 (ALX and ChemR23, respectively)
178                       Both aspirin-triggered lipoxin and resolvin E1 block platelet-derived growth fa
179                                              Lipoxins and aspirin-triggered lipoxins are crucial modu
180                                              Lipoxins and aspirin-triggered lipoxins are lipid mediat
181 d) in resolving exudates, which also contain lipoxins and aspirin-triggered lipoxins generated from a
182           In addition, aspirin-triggered epi-lipoxins and glucocorticoid-regulated annexin 1 might ac
183 ls: inadequate inflammation caused by excess lipoxins and hyperinflammation driven by excess leukotri
184   The relationship between anti-inflammatory lipoxins and proinflammatory leukotrienes might be impor
185 ated with a "resolution deficit" and whether lipoxins and resolvins influence VSMC phenotype.
186     Recently identified lipid mediators (eg, lipoxins and resolvins) play active roles in promoting t
187 ute inflammation, novel mediators, including lipoxins and resolvins, which are members of the special
188 ated by endogenous lipid agonists, including lipoxins and resolvins.
189                              The efficacy of lipoxins and their analog epilipoxins in treating inflam
190                                              Lipoxins and their aspirin-triggered 15-epimers are endo
191 xygenase pathway generating leukotrienes and lipoxins, and the cytochrome P450 (cP450) pathway produc
192 the arachidonic acid-derived prostaglandins, lipoxins, and their natural C15-epimers.
193 port that plasma levels of aspirin-triggered lipoxin are significantly lower in patients with symptom
194                                              Lipoxins are anti-inflammatory lipid mediators that modu
195                                              Lipoxins are biologically active eicosanoids with anti-i
196               Lipoxins and aspirin-triggered lipoxins are crucial modulators of proinflammatory respo
197                  It is currently unclear how lipoxins are efficiently formed from precursors or if th
198                                              Lipoxins are endogenous eicosanoids that demonstrate ant
199 , we provide evidence for a pathway by which lipoxins are generated in macrophages as a consequence o
200                                              Lipoxins are host anti-inflammatory molecules that play
201 uggests that, while excess anti-inflammatory lipoxins are host detrimental during mycobacterial infec
202               Lipoxins and aspirin-triggered lipoxins are lipid mediators generated from arachidonic
203                                Resolvins and lipoxins are lipid mediators generated from essential po
204                                              Lipoxins are potent anti-inflammatory mediators for neut
205                                              Lipoxins are potent antiinflammatory lipid mediators tha
206             The use of nature's own molecule lipoxin as a drug is promising.
207                             The discovery of lipoxins as a class of endogenous allosteric modulators
208                           Here, we establish lipoxins as key chemical mediators in resistance to M. t
209 n and magnitude of inflammation, joining the lipoxins as signals in resolution.
210  can overwhelm organ protective signaling by lipoxins at ALX/FPR2 receptors.
211 E, which is metabolized to aspirin-triggered lipoxin (ATL), 15-epi-lipoxin A4.
212  treatment increased levels of ASA-triggered lipoxin (ATL; 15-epi-lipoxin A4), and blocking the lipox
213 EX is a property shared by aspirin-triggered lipoxins (ATL) and the glucocorticoid-induced annexin 1
214 pimers of LXA(4), known as aspirin-triggered lipoxins (ATL), that may account for some of the bioacti
215 ipid mediators from the prostaglandin to the lipoxin axis.
216 ptotic PMN gave elevated prostaglandin E(2), lipoxin B(4) and RvE2, whereas zymosan-stimulated PMN sh
217  resolvin D3 (AT-RvD3) and aspirin-triggered lipoxin B4 (AT-LXB4).
218 he formation of the resolving lipid mediator lipoxin B4, likely by interfering with AA cyclization an
219  associated with hematological functions and lipoxin biogenesis and signaling.
220 n in vivo and suggest that the inhibition of lipoxin biosynthesis could serve as a strategy for enhan
221      This is the first report of a defect in lipoxin biosynthesis in severe asthma, and suggests an a
222                                 One model of lipoxin biosynthesis involves sequential metabolism of a
223 holipase A2, and its conversion to bioactive lipoxins by 5-lipoxygenase.
224  side of the coin, reporting that endogenous lipoxins compromise immune-mediated control of Mycobacte
225                          We report here that lipoxin concentrations in airway fluid were significantl
226 nsively investigated, LXB4, the less studied lipoxin, emerged to be more potent in protection.
227  also contain lipoxins and aspirin-triggered lipoxins generated from arachidonic acid.
228                                              Lipoxin generation and its relationship to PGE2 and LTB4
229 ctivity in the cystic fibrosis lung and that lipoxins have therapeutic potential in this lethal autos
230                                  The role of lipoxins in the control and resolution of inflammation i
231 anti-inflammatory actions of aspirin-induced lipoxins in vivo.
232 harnessing the pleiotropic activities of the lipoxins is a strategy with considerable therapeutic pro
233 riming by inducing the release of a mosquito lipoxin/lipocalin complex.
234  Here we show that this factor consists of a Lipoxin/Lipocalin complex.
235 estigated the potential of aspirin-triggered lipoxin (LX) A4 analog (ATLa), resolving (Rv) D1, and Rv
236          The actions of an aspirin-triggered lipoxin (LX) analog and RvE1 in a human disease, localiz
237               Recently, we demonstrated that lipoxin (LX)A(4), an eicosanoid mediator that depends on
238                                              Lipoxins (LX) and their aspirin-triggered 15-epimer endo
239                                              Lipoxins (LX) are arachidonate-derived pro-resolving med
240                                              Lipoxins (LX) are bioactive eicosanoids that can be form
241                                              Lipoxins (LX) are proresolution lipid mediators that inh
242 erated during cell-cell interactions are the lipoxins (LX, including LXA(4) and B(4)), a distinct cla
243 ), and the biosynthesis interaction product, lipoxin LXA4.
244                                          The lipoxins LXA4 and LXB4 are small lipid mediators that ac
245                                              Lipoxins (Lxs) and aspirin-triggered epi-Lxs (15-epi-LxA
246                                              Lipoxins (LXs) are eicosanoid mediators that play key co
247                 In view of the importance of lipoxins (LXs) in resolving inflammation, we investigate
248 nd II display both beneficial roles, such as lipoxins (LXs) that stereoselectively signal counterregu
249  B(4) and 20-OH-leukotriene B(4), as well as lipoxin marker 5,15-diHETE.
250 s a pathophysiologically important defect in lipoxin-mediated anti-inflammatory activity in the cysti
251 ts of the immune response, and inhibition of lipoxin-mediated anti-inflammatory responses, which corr
252 s with neutrophils, and we hypothesized that lipoxin mediators regulate formation of neutrophil-plate
253        Together our results demonstrate that lipoxins negatively regulate protective Th1 responses ag
254 iators that include arachidonic acid-derived lipoxins, omega-3 fatty acid eicosapentaenoic acid-deriv
255 lowing acute injury, while inhibition of key lipoxin pathway components exacerbated injury-induced da
256 accumulation of the cyclooxygenase-2-derived lipoxin precursor 15-hydroxyeicosatetraenoic acid (15-HE
257 their ability to convert arachidonic acid to lipoxins, predominantly Lipoxin A4.
258                                    Thus, epi-lipoxins, produced after aspirin acetylation of inducibl
259 ate leukotriene synthesis but also stimulate lipoxin production in inflammatory cells that do not exp
260         Recent studies implicating deficient lipoxin production in the pathogenesis of diverse inflam
261 ies of lipid mediators, including resolvins, lipoxins, prostaglandins, and leukotrienes, as well as l
262 olizing arachidonic acid derivatives such as lipoxins, prostaglandins, hydroxyeicosatetraenoic acids
263      The antiinflammatory role of peripheral lipoxins raises the hypothesis that similar neuraxial sy
264  circuit via formyl peptide receptor (FPR) 2/lipoxin receptor (ALX) (Fpr2/3 in mouse) in global cereb
265 hese effects were partially mediated via the lipoxin receptor (ALX), because they were significantly
266 rial protein release using ELISA, quantified lipoxin receptor (FPR2/ALX) mRNA expression using qRT-PC
267 d airway levels of formyl peptide receptor 2-lipoxin receptor (FPR2/ALXR), LXA4, and its counterregul
268 -7-trihydroxyheptanoic acid methyl ester), a lipoxin receptor agonist, has been previously confirmed
269 gene deletion revealed the importance of the lipoxin receptor ALX for effective lipoxin signaling.
270 at 5-lipoxygenase-dependent (5-LO-dependent) lipoxins regulate host IL-12 production in vivo.
271      This linkage opens the possibility that lipoxins regulate spinal nociceptive processing though t
272                              In this regard, lipoxins represent a unique class of lipid mediators tha
273 lammatory leukotrienes and anti-inflammatory lipoxins requires the enzyme 5-lipoxygenase (5-LOX).
274 o-resolving lipid mediators that include the lipoxin, resolvin, protectin and maresin families, colle
275                  Given the potent actions of lipoxins, resolvins, and protectins in models of human d
276 y, and proresolving lipid mediators (such as lipoxins, resolvins, and protectins) may suppress proinf
277 cialized proresolving lipid mediators (SPMs; lipoxins, resolvins, and protectins) stimulate resolutio
278  endogenous chemical mediators, for example, lipoxins, resolvins, and protectins.
279 ized proresolving lipid mediators, including lipoxins, resolvins, maresins, and protectins.
280 M) constitute separate families that include lipoxins, resolvins, protectins, and maresins, each deri
281 ialized proresolving mediators, specifically lipoxins, resolvins, protectins, and maresins.
282    Among these, lipid mediators, such as the lipoxins, resolvins, protectins, and newly identified ma
283  (SPM) includes essential fatty acid-derived lipoxins, resolvins, protectins, and, most recently, mar
284 research focusing on how the virus modulates lipoxin secretion and warrants further investigation of
285 OX-2-derived mediators, in part via enhanced lipoxin signaling, and carry potential therapeutic impli
286 ce of the lipoxin receptor ALX for effective lipoxin signaling.
287 asthma (SA), display defective generation of lipoxin signals despite glucocorticoid therapy.
288 r arachidonic acid oxygenase activities, the lipoxin synthase activities of 15-lipoxygenating ALOX15
289  evolutionary alterations, we quantified the lipoxin synthase activity of 12-lipoxygenating (rhesus m
290 ssibility that pharmacological inhibition of lipoxin synthesis may provide a method of augmenting ine
291 oduct is transformed via 5-LOX into epimeric lipoxins, termed 15-epi-lipoxins (15-epi-lipoxin A4 [e-L
292 metabolites while promoting the formation of lipoxins, thus supporting inflammatory resolution.
293                                              Lipoxin treatment on CRISPR/CAS9 technology-mediated ALX
294 nvestigation of the therapeutic potential of lipoxin using in vitro cell models for KS and PEL.
295                          Injection of either lipoxin was sufficient for neuroprotection following acu
296                                              Lipoxins, which are endogenously produced lipid mediator
297 d-derived prostaglandins and leukotrienes to lipoxins, which initiate the termination sequence.
298 on of anti-inflammatory mediators, including lipoxins, which limit the host inflammatory response and
299 s, as well as arachidonic acid-derived (n-6) lipoxins, which promote resolution of inflammation, clea
300 ries resolvins, protectin D1, maresin 1, and lipoxins) with respect to inflammatory lipid mediators (

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top